NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to underserved patients in the developing world.   To date, NCC has received more than 10 million international units of ReFacto® Antihemophilic Factor (Recombinant), a therapy used for the treatment and prevention of bleeding in people with hemophilia A, to assist patients who otherwise would have little opportunity for adequate treatment.    The value of this donation is more than $13 million, and it will help many hundreds of hemophilia patients around the world.

"Pfizer is dedicated to developing and delivering innovative hemophilia therapies and we are proud of our partnership with the National Cancer Coalition, which is helping to distribute Pfizer-donated factor product to patients in the global hemophilia community," says Jean-Michel Halfon, President and General Manager, Emerging Markets, Pfizer. "We are committed to working with partner organizations like NCC to provide access to hemophilia medicines to patients who need them most."

Pfizer's donation will help to bring much-needed hemophilia therapy to patients who may be untreated or inadequately treated.  In addition, these donations help to support the development of the infrastructure which creates long term value beyond the donation itself.  This current donation to the National Cancer Coalition is part of the largest hemophilia donation that has ever been made in Pfizer's history.

"Our organization is dedicated to providing the resources and tools needed in the treatment and prevention of cancer, hemophilia, and other serious diseases and illnesses throughout the world," says Robert Landry, President of the National Cancer Coalition.  "Product donations such as Pfizer's are essential to addressing the needs of the patients and families that we serve globally."   National Cancer Coalition, a non-governmental organization (NGO), is a preferred partner of Pfizer and the two organizations have collaborative projects in a number of other areas including cancer, depression, and arthritis.  

Source:

National Cancer Coalition

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered tool predicts gene activity in cancer cells from biopsy images